-
Appendix to ACLA Response to Draft Local Coverage Determinations, Genetic Testing for Oncology
-
Letter from Leading Cancer-Related Provider Groups and Patient Advocates on Genetic Testing for Oncology
-
Understanding the Role of Clinical Laboratories in Supporting Substance Abuse Recovery
September 7, 2023 update: Based on discussions with ACLA and other key stakeholders, CMS has made the decision to withdraw the policy change referenced in the ... Read More -
ACLA Submits Comments on CMS Transitional Coverage For Emerging Technologies Notice
-
ACLA Submits Comments on CMS Pre-Exposure Prophylaxis (PrEP) Proposed NCD
-
ACLA Submits Comments on the CDC’s NCVHS ICD-11 RFI
-
ACLA Submits Comments on Palmetto Special Stains/IHC Proposed LCD
-
Letter to ONDCP on NCCI Edits for Drug Testing
-
ACLA Submits Comments on Senate HELP Committee RFI on Reauthorization of the Pandemic All-Hazards Preparedness Act (PAHPA)
-
Letter from Leading Patient Advocacy Organizations on Passing the Saving Access to Laboratory Services Act
